Multispectral Optoacoustic Tomography for Advanced Imaging of Centronuclear Myopathy

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2+
SponsorUniversity of Erlangen-Nürnberg Medical School

About this trial

Twenty patients with centronuclear myopathy and twenty age- and sex-matched, muscle-healthy controls will undergo diagnostic examination. Study participants will undergo physical examination, clinical and functional testing, and multispectral optoacoustic tomography (MSOT) scanning at predefined muscle sites (paraspinal muscles, trapezius muscle, deltoid muscle, forearm flexors, quadriceps muscle, adductor muscles, ischiocrural muscles, triceps surae muscle, and tibialis anterior).

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

Pregnancy

Nursing mothers

Tattoo in the area of the examination field

Subcutaneous fatty tissue > 3 cm

Trial population

n= 20 CNM n = 20 HV

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • MSOT

    Diagnostic test

    Multispectral optoacoustic tomography (MSOT) enables the detection of specific endogenous chromophores such as collagen, myoglobin or haemoglobin using a non-invasive approach comparable to conventional ultrasound. Instead of sound waves, MSOT illuminates the tissue with near-infrared light of transient energy, which is absorbed and leads to thermoelastic expansion of certain molecules. This expansion generates ultrasound waves that are detected by the same device. The multispectral illumination and unmixing then enable the precise localization and quantification of muscle-specific subcellular structures. MSOT has already shown the potential to visualize the muscle structure and clinical extent of muscle disease in patients with Duchenne muscular dystrophy, spinal muscular atrophy and the late-onset Pompe disease (LOPD) and to distinguish these patients from healthy volunteers. To date, there is no optoacoustic data on CNM.

Treatment groups

40 Participants
are divided into 2 treatment groups
Group A: CNM1 intervention
Group B: HV1 intervention

Trial outcomes

Primary outcomes

1

Optoacoustic spectrum of MSOT Imaging (all in arbitrary units)

Comparison of optoacoustic spectrum from patients with diagnosed CNM and their age- and sex matched Healthy Volunteers

Time frame
Day 1

Secondary outcomes

1

Comparison of MSOT-Derived Hemoglobin and Myoglobin Signals

Quantitative comparison of MSOT-derived hemoglobin and myoglobin signals (arbitrary units).

Time frame
Day 1
2

Comparison of Oxygenated vs. Deoxygenated Hemoglobin Signal

Quantitative comparison of oxygenated and deoxygenated hemoglobin signals.

Time frame
Day 1
3

Comparison of Oxygenated Hemoglobin and Lipid Signal

Quantitative comparison of oxygenated hemoglobin and lipid signals.

Time frame
Day 1
4

Comparison of deoxygenated Hemoglobin and Lipid Signal

Quantitative comparison of deoxygenated hemoglobin and lipid signals.

Time frame
Day 1

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.